ASIAN PHYTOCEUTICALS
PUBLIC COMPANY LIMITED

APCO

Opportunity Day Q1/2568

27 พ.ค. 2568

ผลิตภัณฑ์ของ APCO ได้รับการพิสูจน์ประสิทธิภาพจากงานวิจัยและตีพิมพ์เผยแพร่แล้ว

ในวารสารนานาชาติ Clinical Immunology & Research และ Food Science and Nutrition

ยืนยันถึงประสิทธิภาพในการจัดการกับเชื้อ HIV/AIDS และไวรัสชนิดอื่นๆ ตลอดจนประสิทธิภาพในการจัดการกับเซลล์มะเร็ง โรคแพ้ภูมิตัวเอง และฟื้นฟูสุขภาพให้อายุยืนโดยใช้วิธีการธรรมชาติ

ByeByeHIV นวัตกรรมแห่งชาติไทย สร้างประวัติศาสตร์การรักษา HIV เป็นครั้งแรกของโลก ตั้งแต่การพบเชื้อเมื่อ 40 ปีที่แล้ว

พิมพ์เผยแพร่ใน Journal of Clinical Immunology and Research ISSN 2639-8494, https://www.scivisionpub.com/abstract-display.php?id=3167

SCIVISION PUBLISHERS

Abstract

ByeByeHIV with Thai Innovation

Authors: *Pichaet Wiriyachitra, Sirithip Wiriyachitra, Siriporn Wonghiranyingyot, Ampai Panthong, Ganigah Ruanjahn, Souwalak Phongpaichit, Wilawan Mahabusarakam.*

Review Article ISSN 2639-8494
Clinical Immunology & Research

ByeByeHIV with Thai Innovation

Pichaet Wiriyachitra[1]*, Sirithip Wiriyachitra[1], Siriporn Wonghiranyingyot[1], Ampai Panthong[2], Ganigah Ruanjahn[3], Souwalak Phongpaichit[4] and Wilawan Mahabusarakam[4]

[1]Asian Phytoceuticals Public Company Limited, Thailand
[2]Chiang Mai University, Thailand
[3]Boromarajonani College of Nursing, Chiang Mai Thailand
[4]Prince of Songkla University, Thailand

*Correspondence:
Wiriyachitra P, Asian Phytoceuticals Public Company Limited, Thailand, Email: byebyehiv@apco.co.th and pw@apco.co.th, Tel: 1662 646 4882.

Received: 04 Jan 2024; Accepted: 18 Feb 2024; Published: 25 Feb 2024

Citation: Wiriyachitra P, Wiriyachitra S, Wonghiranyingyot S, et al. *ByeByeHIV* with Thai Innovation. Clin Immunol Res. 2024; 8(1): 1-7.

ABSTRACT

ByeByeHIV is defined as the condition in which HIV/AIDS-infected individuals can reduce their HIV load to undetectable levels without the consumption of antiviral drugs and enjoy healthy living. It also refers to the condition where HIV infected individuals, who have consumed antiviral drugs as the treatment but can no longer tolerate the drugs' side effects, can stop taking the drugs and enjoy living a healthy life with undetectable HIV. ByeByeHIV innovation is composed of synergistic extracts from 3 types of edible plants, namely marigosteen, black sesame, soybean, guava and Centella asiatica. It has been proven effective in stimulating Th1 and Th17 cells, which boosts the potency of killer T cells to eliminate HIVinfected cells. It has also been proven to repair the telomere damage caused by HIV and the side effects of antiviral drugs. The innovation has successfully helped over 6,000 HIV/AIDSinfected individuals increase their CD4 count, decrease viral load, and improve their quality of life. In 2014, the first HIV-infected person volunteered to take the innovation instead of antiviral drugs. His HIV load dropped to an undetectable levels within 12 months and he remained in good health with undetectable HIV for the past 8 years. In 2022, the standard procedure to help HIV/AIDS-infected individuals achieve ByeByeHIV was established. In November 2023, 24 HIV-infected individuals have achieved ByeByeHIV without taking antiviral drugs; among them 6 have stopped taking ByeByeHIV formula and still remain undetected for HIV. 26 HIV/AIDS patients who had taken antiviral drugs for 5-30 years have been able to stop taking antiviral drugs and still enjoy good health, the first person in the group has been off antiviral drugs for 36 months; among them 3 have stopped taking ByeByeHIV formula and still remain undetected for HIV. The number of HIV/AIDS patients who have achieved ByeByeHIV continues to increase in Thailand. We are now advocating this ByeByeHIV innovation as the first safe and effective plant-based immunotherapy to benefit HIV/AIDS-infected individuals globally. In the presentation, there will be additional information on the mode of action of the innovation, the blood profiles both before and after and the time spent to achieve ByeByeHIV of the 50 infected individuals.

Professor Pichaet Wiriyachitra is the CEO of Asian Phytoceuticals Public Company Limited, a company listed in Stock Exchange of Thailand, to engage in research, development and commercialization of health products derived natural extracts. Dr.Pichaet received the BSc.Hons (Organic Chemistry) from University of Western Australia in 1970 and Ph.D. (Organic Chemistry) from University of Tasmania in 1972. He was a NIH Post-doctoral Fellow at University of Connecticut, America in 1974 and a NSF Post-doctoral Fellow at University of Pennsylvania, America in 1976. His research interests in the Prince of Songkla University and Chiang Mai University in Thailand include the development of Balancing Immunity (BIM) products for autoimmune symptoms and immune- deficient symptoms.



พิมพ์เผยแพร่ใน Journal of Clinical Immunology and Research

ISSN 2639-8494, https://www.scivisionpub.com/abstract-display.php?id=3769

ผู้ติดเชื้อที่ไม่เคยใช้ยามาก่อน ByeByeHIV ได้ 40 ราย
และมีผู้ที่หยุดใช้นวัตกรรมแล้ว 15 ราย ก็ยังตรวจไม่พบเชื้ออย่างต่อเนื่อง

Research Article ISSN 2639-8494

Clinical Immunology & Research

ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases without the Use of ARV Drugs (Group A)

Pichaet Wiriyachitra[1]*, Sirithip Wiriyachitra[1], Siriporn Wonghiranyingyot[1], Ampai Panthong[2], Ganigah Ruanjahn[3], Souwalak Phongpaichit[4] and Wilawan Mahabusarakam[4]

[1]*Asian Phytoceuticals Public Company Limited. Thailand.*

[2]*Chiang Mai University, Thailand.*

[3]*Boromarajonani College of Nursing, Chiang Mai Thailand.*

[4]*Prince of Songkla University, Thailand.*

***Correspondence:**
Wiriyachitra P, Asian Phytoceuticals Public Company Limited, Thailand, Tel: +662 646 4882.

Received: 05 Jan 2025; **Accepted:** 15 Feb 2025; **Published:** 25 Feb 2025

Citation: Pichaet Wiriyachitra, Sirithip Wiriyachitra, Siriporn Wonghiranyingyot, et al. ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases without the Use of ARV Drugs (Group A). Clin Immunol Res. 2025; 9(1): 1-5.

พิมพ์เผยแพร่ใน Journal of Clinical Immunology and Research

ISSN 2639-8494, https://www.scivisionpub.com/abstract-display.php?id=3770

ผู้ติดเชื้อที่ใช้ยาอยู่แล้วแต่ทนผลข้างเคียงไม่ได้ หยุดใช้ยาได้ ByeByeHIV แล้ว 40 ราย และมีผู้ที่หยุดใช้นวัตกรรมแล้ว 15 ราย ก็ยังตรวจไม่พบเชื้ออย่างต่อเนื่อง

Research Article

ISSN 2639-8494

Clinical Immunology & Research

ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases with Prior Use of ARV Drugs (Group B)

Pichaet Wiriyachitra[1]*, Sirithip Wiriyachitra[1], Siriporn Wonghiranyingyot[1], Ampai Panthong[2], Ganigah Ruanjahn[3], Souwalak Phongpaichit[4] and Wilawan Mahabusarakam[4]

[1]*Asian Phytoceuticals Public Company Limited, Thailand.*

[2]*Chiang Mai University, Thailand.*

[3]*Boromarajonani College of Nursing, Chiang Mai Thailand*

[4]*Prince of Songkla University, Thailand.*

*Correspondence:
Wiriyachitra P, Asian Phytoceuticals Public Company Limited, Thailand, Tel: +662 646 4882.

Received: 20 Feb 2025; Accepted: 25 Mar 2025; Published: 03 Apr 2025

Citation: Wiriyachitra P, Wiriyachitra S, Wonghiranyingyot S, et al. *ByeByeHIV* with Plant-Based Immunotherapy: Progress Update on 40 Cases with Prior Use of ARV Drugs (Group B). Clin Immunol Res. 2024; 9(1): 1-11.

สารสกัดพืชกินได้ 5 ชนิด กระตุ้น T-Cell ให้เพิ่มคุณภาพชีวิตของผู้ป่วยมะเร็ง

Ref: https://www.scivisionpub.com/abstract-display.php?id=3355

Cancer Patient Life Quality Improvement by T-Cell Stimulation with Five Edible Plants

Authors: Pichaet Wiriyachitra, Preeya Leelahagul , Sirithip Wiriyachitra , Ampai Panthong, Sakda Sreesangkom.First published: 20 November 2023, Link; https://www.scivisionpub.com/abstract-display.php?id=3355

มังคุดเสริมฤทธิ์ให้ย้อนวัยชะลอวัย ด้วยการเพิ่มความยาวเทโลเมียร์

พิมพ์เผยแพร่ในวารสารวิชาการนานาชาติ

https://doi.org/10.1002/fsn3.3851

Received: 30 June 2023 | Revised: 5 November 2023 | Accepted: 8 November 2023

DOI: 10.1002/fsn3.3851

Food Science & Nutrition Open Access WILEY

ORIGINAL ARTICLE

Efficacy of a dietary supplement derived from five edible plants on telomere length in Thai adults: A randomized, double-blind, placebo-controlled trial

Kemika Praengam[1] | Siriporn Tuntipopipat[1] | Chawanphat Muangnoi[1] | Chatdao Jangwangkorn[2] | Olan Piamkulvanich[3]

การย้อนวัยและเพิ่มคุณภาพชีวิตในระหว่างการจัดการมะเร็งด้วยมังคุดเสริมฤทธิ์

พิมพ์เผยแพร่ในวารสารวิชาการนานาชาติ

https://www.scivisionpub.com/abstract-display.php?id=3575

Research Article ISSN 2639-8494

Clinical Immunology & Research

Age Reversal by Telomere Elongation Without Cancer Risk

Pichaet Wiriyachitra[1*], Preeya Leelahagul[1], Sirithip Wiriyachitra[1], Ampai Panthong[2] and Sakda Sreesangkom[1]

[1]*Asian Phytoceuticals Public Company Limited, Thailand.*

[2]*Chiang Mai University, Thailand.*

***Correspondence:**
Wiriyachitra P, Asian Phytoceuticals Public Company Limited, Thailand, Tel: +662 646 4882.

Received: 20 Sep 2024; **Accepted:** 14 Nov 2024; **Published:** 25 Nov 2024

การรักษาและป้องกันมะเร็งอย่างได้ผลด้วยภูมิคุ้มกันบำบัด จากพืชกินได้

Ref: https://www.scivisionpub.com/abstract-display.php?id=3608

Abstract

Effective Cancer Treatment and Prevention with Plant-Based Immunotherapy

Authors: *Pichaet Wiriyachitra, Preeya Leelahagul, Sirithip Wiriyachitra, Ramida Watanapokasin, Jannatthabhorn Janprasert, Sakda Sreesangkom.*

Cancino®, a dietary supplement registered with the Thai FDA, was developed to prevent cancer, which has been increasing at an alarming rate, by building on the previous success of the formula of Mylife/Mylife100® in cancer treatment. The formulation is modified from that of Mylife/Mylife100® by using a different concentration of active ingredients from five edible plants, namely pennywort leaves, black sesame seeds, soybeans, guava fruit, and mangosteen aril. Consumers with low immunity who took 3 capsules of Cancino® per day before breakfast over a study period of 8 weeks experienced increased immunity as evidenced by the sharp increases in lymphocytes, CD4 and CD8 T cells. Most participants also demonstrated significant increases in their absolute mean telomere length simultaneously as they increased their immunity. In addition, they all exhibited autophagy induction, as indicated by the increase in the expression of Atg12 and LAMP1. All these results demonstrated that Cancino® is effective in cancer prevention, achieved through the combined effects of increased T cells, telomere elongation in previously existing and newly increased T cells, and autophagy induction.

View/Download pdf

ประสิทธิภาพในการดูแลปัญหา Rheumatoid Arthritis ด้วยสารสกัดจากมังคุดเสริมฤทธิ์

พิมพ์เผยแพร่ใน Journal of Clinical Immunology and Research

ISSN 2639-8494, https://www.scivisionpub.com/abstract-display.php?id=3387

SCIVISION PUBLISHERS

Home | Journals | Submit Manuscript | Abstracting and Indexing | Contact Us

Clinical Immunology & Research

Open Access

ISSN: 2639-8494

Journal Home | Aims and Scope | Editorial Board | Abstracting and Indexing | Guidelines | Articles Inpress | Current Issue | Archive Page

Abstract

Balancing Immunity with a Dietary Supplement Derived from Five Edible Plants for Management of Rheumatoid Arthritis

Authors: *Sirithip Wiriyachitra, Pichaet Wiriyachitra, Ampai Panthong.*

The development of specific agents affecting T helper cell subpopulations has gained considerable attention in recent years, with natural products emerging as potential immune modulators for various diseases, including rheumatoid arthritis (RA). This study investigates the immunomodulatory effects of Arthrinox/BIM-A, a dietary supplement derived from five edible plants, namely black sesame, guava fruit, mangosteen aril, pennywort leaves, and soy protein, on the regulation of T helper cell subpopulations. Twelve healthy volunteers were divided into two groups, one receiving a placebo and the other taking Arthrinox/BIM-A capsules for 15 days. Blood samples were collected before and after the supplementation period, and peripheral blood mononuclear cells (PBMCs) were isolated and stimulated to assess cytokine production. In the present study, we demonstrated that Arthrinox/BIM-A can modulate the immune cell functions by reducing the production of several pro-inflammatory cytokines, including IL-2, IL-17 and TNF-α. Arthrinox/BIM-A is therefore suggested as the food supplement for balancing immunity in the management of RA patients.

View/Download pdf

Chat with us

Research Article ISSN 2639-8494

Clinical Immunology & Research

Balancing Immunity with a Dietary Supplement Derived from Five Edible Plants for Management of Rheumatoid Arthritis

Sirithip Wiriyachitra, Pichaet Wiriyachitra* and Ampai Panthong

Asian Phytoceuticals Public Company Limited, Bangkok, Thailand.

*Correspondence:
Wiriyachitra P, Asian Phytoceuticals Public Company Limited, Thailand, Tel: +662 646 4882.

Received: 08 Jun 2024; Accepted: 13 Jul 2024; Published: 20 Jul 2024

Citation: Sirithip Wiriyachitra, Pichaet Wiriyachitra, Ampai Panthong. Balancing Immunity with a Dietary Supplement Derived from Five Edible Plants for Management of Rheumatoid Arthritis. Clin Immunol Res. 2024; 8(1): 1-3.

ABSTRACT

The development of specific agents affecting T helper cell subpopulations has gained considerable attention in recent years, with natural products emerging as potential immune modulators for various diseases, including rheumatoid arthritis (RA). This study investigates the immunomodulatory effects of Arthrinox/BIM-A, a dietary supplement derived from five edible plants, namely black sesame, guava fruit, mangosteen aril, pennywort leaves, and soy protein, on the regulation of T helper cell subpopulations. Twelve healthy volunteers were divided into two groups, one receiving a placebo and the other taking Arthrinox/BIM-A capsules for 15 days. Blood samples were collected before and after the supplementation period, and peripheral blood mononuclear cells (PBMCs) were isolated and stimulated to assess cytokine production.

In the present study, we demonstrated that Arthrinox/BIM-A can modulate the immune cell functions by reducing the production of several pro-inflammatory cytokines, including IL-2, IL-17 and TNF-α. Arthrinox/BIM-A is therefore suggested as the food supplement for balancing immunity in the management of RA patients.

Keywords
Balancing immunity, Rheumatoid arthritis, Mangosteen, Autoimmune, TNF-α, Interleukin 17, Arthrinox/BIM-A.

Introduction
During the last decades, the development of specific agents affecting T helper cell subpopulations, i.e., Th1, Th2 and Th17 differentiation, has drawn special attention. Many natural products have been reported as effective agents for balancing the immune response by regulating the differentiation of T helper cell subpopulations. These products have the potential to be immune modulators for the treatment of various diseases, including infectious diseases, cancers, autoimmune diseases and arthritis.

In this study, we aim to study the immunomodulatory effects of Arthrinox/BIM-A, a dietary supplement consisting of five edible plants, namely black sesame, guava fruit, mangosteen aril, pennywort leaves and soy protein. We investigate the possible effect of Arthrinox/BIM-A on the control of T helper cell subpopulation differentiation.

Objective
The objective of this study is to investigate the possible effects of Arthrinox/BIM-A on the regulation of T helper cell subpopulations. The levels of various cytokines in blood collected from healthy donors before and after taking Arthrinox/BIM-A capsules for 15 days were compared.

Study Approaches
Study Subjects
- 12 healthy volunteers: 6 males and 6 females
- Age range: 20-55 years old
- The recruited volunteers were divided into 2 groups:
  - **Group 1:** taking placebo; 6 subjects
  - **Group 2:** taking Arthrinox capsule; 6 subjects

Blood Collection
Blood samples (5 ml, using heparin as an anticoagulant) were collected from each subject on day 0. According to their groups, subjects took either Arthrinox/BIM-A capsules or placebo (4 capsules/day) every day for 15 days. Afterwards, blood samples

Clin Immunol Res, 2024 Volume 8 | Issue 1 | 1 of 3



(5 mL using heparin as an anticoagulant) were collected for the second time on day 16.

Study of the Effect of the Arthrinox/BIM-A Capsule on the Regulation of T Helper Cell Subpopulations
Peripheral blood mononuclear cells (PBMCs) were isolated from the collected blood using Ficoll-Hypaque gradient centrifugation. The PBMCs were then stimulated in vitro with or without anti-CD3 monoclonal antibodies (clones OKT3) and cultured for 24 hours at 37°C in a CO2 incubator. The cell culture supernatants were collected and centrifuged at 20,000 rpm for 2 minutes. The cell-free supernatants were separated and stored at -70°C for determination of cytokines.

Results
The stimulation indexes of various cytokines in subjects taking the Arthrinox/BIM-A capsules and placebo were calculated and compared. Normalization was performed using subjects taking the placebo. The percentage enhancement and reduction in subjects taking the Arthrinox/BIM-A capsules are shown in the figure below. The results indicate that Arthrinox/BIM-A capsules reduced the production of IL-2 and IL-17 and significantly reduced the production of TNF-α.

Tumor necrosis factor (TNF) is present at biologically significant levels in rheumatoid arthritis (RA) synovial tissue and fluid, and seems to parallel the extent of both inflammation and bone erosion. TNF triggers several of the most central and critical events in acute and chronic synovial inflammation, ultimately leading to the tissue destruction characteristic of RA, including the induction of multiple additional cytokines and chemokines, the expression of adhesion molecules and increased levels of class I MHC determinants and the synthesis and release of proteases and prostaglandin E2 by synovial fibroblasts (which is important in the erosion of cartilage and bone) and synovial neoangiogenesis. Some data suggest that monocytes from patients with early RA hyperproduce TNF when activated. Taking all the data into consideration, one can reasonably conclude that TNF is one of the most important cytokines in the pathogenesis of RA [1].

RA is a chronic inflammatory disease characterized by hyperplasia of the synovium and an excess of inflammatory cells, leading to progressive destruction of the joints. In RA, several cytokines, e.g., interleukin (IL)-1, IL-6, IL-8, IL-12, IL-17, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and granulocyte-macrophage colony-stimulating factor (GM-CSF), are involved in almost all aspects of articular inflammation and destruction. TNF-α has been considered a pivotal cytokine in the pathogenesis of RA, as significant clinical and laboratory evidence has been obtained by TNF-α blockade [2]. It has been reported that treatment of RA patients with infliximab (Remicade), a chimeric antibody specific for human TNF-α, substantially reduced the signs and symptoms of the disease, levels of C-reactive protein (CRP) in the serum, and the erythrocyte sedimentation rate (ESR) [3]. This result was confirmed in other multicenter placebo-controlled trials, together with the observation that therapeutic efficacy was enhanced when infliximab was coadministered with methotrexate. This led eventually to FDA approval of the drug for the treatment of RA [4,5].

IL-17A is the signature cytokine of Th17 cells and has pleiotropic effects on many cell types, inducing the upregulation of NF-κB, HLA class I, and several proinflammatory cytokines, including TNF-α, IL-1β, IL-6, and GM-CSF. Of relevance to the pathogenesis of RA are the effects of IL-17 in driving osteoclastogenesis, leading to bone resorption [6]. Neutralization of IL-17A in mice

Clin Immunol Res, 2024 Volume 8 | Issue 1 | 2 of 3

ประสิทธิภาพในการดูแลปัญหา เบาหวาน ด้วยสารสกัดจากมังคุดเสริมฤทธิ์

พิมพ์เผยแพร่ใน Journal of Clinical Immunology and Research

ISSN 2639-8486, https://www.scivisionpub.com/abstract-display.php?id=3446

Abstract

Balancing Immunity with a Dietary Supplement Derived from Five Edible Plants for Management of Diabetes

Authors: *Sirithip Wiriyachitra, Pichaet Wiriyachitra, Ampai Panthong*

This study investigates the immunomodulatory effects of Diabenox/BIM-D, a dietary supplement derived from five edible plants, namely black sesame, guava fruit, mangosteen aril, pennywort leaves, and soy protein, on the regulation of T helper cell subpopulations. Twelve healthy volunteers were divided into two groups, one receiving a placebo and the other taking Diabenox/BIM-D capsules for 15 days. Blood samples were collected before and after the supplementation period, and peripheral blood mononuclear cells (PBMCs) were isolated and stimulated to assess cytokine production.

In the present study, we demonstrated that Diabenox/BIM-D can modulate the immune cell functions by reducing the production of pro-inflammatory cytokines, including TNF-α, IL-5, IL-12 and IL-17. Diabenox/BIM-D is therefore suggested as the food supplement for balancing immunity in the management of diabetic patients.

View/Download pdf

Research Article ISSN 2639-8486

Clinical Immunology & Research

Balancing Immunity with a Dietary Supplement Derived from Five Edible Plants for Management of Diabetes

Sirithip Wiriyachitra, Pichaet Wiriyachitra* and Ampai Panthong

Asian Phytoceuticals Public Company Limited, Bangkok, THAILAND.

*Correspondence:
Wiriyachitra P, Asian Phytoceuticals Public Company Limited, Thailand, Tel: +662 646 4882.

Received: 29 Jun 2024; Accepted: 13 Aug 2024; Published: 21 Aug 2024

Citation: Sirithip Wiriyachitra, Pichaet Wiriyachitra, Ampai Panthong. Balancing Immunity with a Dietary Supplement Derived from Five Edible Plants for Management of Diabetes. Clin Immunol Res. 2024; 8(2): 1-3.

ABSTRACT

This study investigates the immunomodulatory effects of Diabenox/BIM-D, a dietary supplement derived from five edible plants, namely black sesame, guava fruit, mangosteen aril, pennywort leaves, and soy protein, on the regulation of T helper cell subpopulations. Twelve healthy volunteers were divided into two groups, one receiving a placebo and the other taking Diabenox/BIM-D capsules for 15 days. Blood samples were collected before and after the supplementation period, and peripheral blood mononuclear cells (PBMCs) were isolated and stimulated to assess cytokine production.

In the present study, we demonstrated that Diabenox/BIM-D can modulate the immune cell functions by reducing the production of pro-inflammatory cytokines, including TNF-α, IL-5, IL-12 and IL-17. Diabenox/BIM-D is therefore suggested as the food supplement for balancing immunity in the management of diabetic patients.

Keywords
Balancing immunity, Diabetes, Mangosteen, Autoimmune, TNF-α, IL-5, IL-12, IL-17, Diabenox/BIM-D.

Introduction
The development of specific agents affecting T helper cell subpopulations, i.e., Th1, Th2 and Th17 differentiation, has drawn special attention in the last decades. Many natural products have been reported as effective agents for balancing the immune response by regulating the differentiation of T helper cell subpopulations. These products have the potential to be immune modulators for the treatment of various diseases, including infectious diseases, cancers, autoimmune diseases and diabetes.

In this study, we aim to investigate the immunomodulatory effects of Diabenox/BIM-D, a dietary supplement consisting of five edible plants, namely black sesame, guava fruit, mangosteen aril, pennywort leaves and soy protein. We investigate the possible effect of Diabenox/BIM-D on the control of T helper cell subpopulation differentiation.

Objective
The objective of this study is to investigate the possible effects of Diabenox/BIM-D on the regulation of T helper cell subpopulations. The levels of various cytokines in blood collected from healthy donors before and after taking Diabenox/BIM-D capsules for 15 days were compared.

Study Approaches
Study Subjects
- 12 healthy volunteers: 7 males and 5 females
- Age range: 20-50 years old
- The recruited volunteers were divided into 2 groups:
  - Group 1: taking a placebo; 6 subjects
  - Group 2: taking Diabenox capsules; 6 subjects

Blood Collection
Blood samples (5 mL using heparin as an anticoagulant) were collected from each subject on day 0. According to their groups, subjects took either Diabenox/BIM-D capsules or a placebo (4 capsules/day) every day for 15 days. Afterwards, blood samples (5 mL using heparin as an anticoagulant) were collected for the second time on day 16.

Study of the Effect of the Diabenox/BIM-D Capsule on the Regulation of T Helper Cell Subpopulations
Peripheral blood mononuclear cells (PBMCs) were isolated from the collected blood using Ficoll-Hypaque gradient centrifugation. The PBMCs were then stimulated *in vitro* with or without anti-CD3 monoclonal antibodies (clone OKT3) and cultured for 24 hours at 37°C in a CO2 incubator. The cell culture supernatants were collected and centrifuged at 20,000 rpm for 2 minutes. The cell-free supernatants were separated and stored at -70°C for the determination of cytokines.

Determination of T helper cell cytokines
Cytokines in the cell culture supernatant were determined by FlowCytomix™ (eBioscience, Inc., San Diego, CA, USA) following the manufacturer's protocol. Comparisons of the cytokine levels from un-stimulated PBMCs and stimulated PBMCs in terms of the Stimulation Index on day 0 and day 15 were performed.

Results
The stimulation indexes of various cytokines in subjects taking the Diabenox/BIM-D capsules and the placebo were calculated and compared. Normalization was performed using data from subjects taking the placebo. The percentage enhancement and reduction in subjects taking the Diabenox/BIM-D capsules are shown in the figure below. The results indicate that Diabenox/BIM-D capsules reduced the production of TNF-α, IFN-γ, IL-4, IL-5, IL-9, IL-10, IL-12 and IL-17.

Type 2 diabetes, which is usually associated with obesity or older age, is mostly the result of insulin resistance. In these patients, muscle or adipose cells do not respond adequately to normal levels of insulin produced by intact beta-cells. On the other hand, Type 1 diabetes usually starts in people younger than 30 and is therefore also termed juvenile-onset diabetes, even though it can occur at any age. It is a chronic autoimmune disorder that precipitates in genetically susceptible individuals due to environmental factors [1]. The body's own immune system attacks the beta-cells in the islets of Langerhans of the pancreas, destroying or damaging them sufficiently to reduce and eventually eliminate insulin production. A combination of factors, including a Th1-skewed CD4+ response as well as a deficiency of regulatory T cells, are considered important hallmarks of disease progression [2].

There is sufficient information suggesting that Th1 cells play a major role in diabetes, driving the development of disease via IFN-γ [3]. This includes observations that blockade of IFN-γ [4] or absence of STAT4 [5,6] prevents disease, whereas IL-12 promotes accelerated diabetes [7]. Tumor necrosis factor alpha (TNF-α) has well-described effects on lipid metabolism in the context of acute inflammation, such as in sepsis. Recently, increased TNF-α production has been observed in adipose tissue derived from obese rodents or human subjects, and TNF-α has been implicated as a causative factor in obesity-associated insulin resistance and the pathogenesis of type 2 diabetes. Thus, current evidence suggests that administration of exogenous TNF-α to animals can induce insulin resistance, whereas neutralization of TNF-α can improve insulin sensitivity [8]. In addition, TNF-α shows a significant positive association with insulin secretory capacity when adjusting for the effects of the confounding factors - age, sex and BMI in IGR



มังคุดเสริมฤทธิ์ทำให้เกิดการย้อนวัย แก้ปัญหา Alzheimer ด้วยการเพิ่มขึ้นของ Telomere, Autophagy

พิมพ์เผยแพร่ใน Journal of Clinical Immunology and Research

ISSN 2639-8486, https://www.scivisionpub.com/abstract-display.php?id=

Research Article ISSN 2639-8494

Clinical Immunology & Research

Regenerative Innovation from Fortified Mangosteen Extract

Pichaet Wiriyachitra[1]*, Preeya Leelahagul[1], Ramida Watanapokasin[2], Sirithip Wiriyachitra[1], Jannatthabhorn Janprasert[1] and Sakda Sreesangkom[1]

[1]Asian Phytoceuticals Public Company Limited, Thailand.

[2]Department of Biochemistry, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand.

*Correspondence:
Wiriyachitra P, Asian Phytoceuticals Public Company Limited, Thailand, Tel: +662 646 4882.

Received: 26 Mar 2025; Accepted: 08 May 2025; Published: 16 May 2025

Citation: Wiriyachitra P, Leelahagul P, Watanapokasin R, et al. Regenerative Innovation from Fortified Mangosteen Extract. Clin Immunol Res. 2025; 9(1): 1-6.

ABSTRACT

This article describes a clinical study on a newly developed formulation, Fortified Mangosteen Extract, involving 19 participants, with the specific aim of investigating alterations in their T cells, cytokines, telomeres and autophagy. The results show that the formulation had no effect on the number of white blood cells related to immunity but caused a decrease in pro-inflammatory cytokines, TNF-α, IL-6, IL-17A, IL-12/IL-23 (p40), and IFN-γ, while increasing the level of IL-10 that regulates other pro-inflammatory cytokines. It also slowed telomere shortening in 6 participants and lengthened telomeres in 13 participants, demonstrating its anti-aging and age-reversal effects, respectively. Most importantly, the formulation induced autophagy-related gene expressions, LAMP1, LC3A, ATG5 and BECN1, during the study. In conclusion, this study clearly demonstrates the health benefits of Fortified Mangosteen Extract for individuals with autoimmune diseases, particularly its potential in the prevention and treatment of Alzheimer's disease.

VDO นพ.บรรสาน ตันตสวัสดิ์

VDO คุณสลวย ภักดีบาง

ผลิตภัณฑ์เหล่านี้
จำหน่ายในประเทศไทยผ่าน

BIM Advisor

APCO ผนึกพันธมิตรไนจีเรีย
นวัตกรรมไทยจัดการกับปัญหาสุขภาพทุกประเทศในทวีปแอฟริกา

4 มิถุนายน 2568

APCO ลงนามสัญญาซื้อขาย ผลิตภัณฑ์นวัตกรรมสุขภาพกับ AGBOGU Healthcare Products Limited จากประเทศไนจีเรีย

ลงนามสัญญาซื้อขายกับระหว่าง

Chief Dr. Ikechukwu C. Agbogu ผู้ก่อตั้ง/ประธานบริหาร AGBOGU Healthcare Products Limited และ ศ.ดร.พิเชษฐ์ วิริยะจิตรา ประธานกรรมการบริหาร APCO

ประสบการณ์การทำธุรกิจ
Chief (Dr.) IKECHUKWU C. AGBOGU

- รับเหมาก่อสร้างและงานโยธา
- ผู้แทนจำหน่ายผลิตภัณฑ์เหล็กกล้าจากประเทศยุโรป
- ผู้นำเข้าผลิตภัณฑ์ปิโตรเลียมสำเร็จรูปจากประเทศยุโรป

ประสบการณ์การทำธุรกิจ
Chief (Dr.) IKECHUKWU C. AGBOGU

ปัจจุบันจัดตั้งบริษัทเพื่อนำเข้าสินค้าจากประเทศไทย เพื่อจัดจำหน่ายในประเทศไนจีเรียและแอฟริกา

- AGBOGU Healthcare Products Limited.
- AGBOGU THAI - ASIA RICE COMPANY LIMITED



AGBOGU Healthcare Products Limited.

จะจัดจำหน่ายผลิตภัณฑ์ของ APCO ในประเทศ Nigeria และประเทศในทวีป Africa ซึ่งมีประชากรรวม 1,200 ล้านคน เพื่อนำไปใช้ดูแล ผู้ติดเชื้อ HIV/AIDS รวมถึงผู้ป่วย โรคมะเร็ง, โรคร้ายแรง และโรคแพ้ภูมิตัวเอง

ผลิตภัณฑ์ที่จะจัดจำหน่ายให้
AGBOGU Healthcare Products Limited.

- Mylife
- Mylife100
- Mylife100A
- BIM A
- BIM C
- BIM D
- BIM O
- BIM B
- BIM F
- BIM H
- NOVIR
- Cancino


DIRECTIONS : 2 capsules, 2-3 times a day, before meal or bedtime.
ขนาดรับประทาน : 2 แคปซูล วันละ 2-3 ครั้ง ก่อนอาหารหรือก่อนนอน
MANUFACTURED BY :
BANGKOK OFFICE:
ASIAN PHYTOCEUTICALS PUBLIC COMPANY LIMITED 89 AIA CAPITAL CENTER BUILDING 30TH FLOOR, RATCHADAPISEK Rd, DIN-DAENG, BANGKOK, 10400 THAILAND.
MANUFACTURING FACILITY:
NORTHERN REGION INDUSTRIAL ESTATE 84/3 MOO 4, HIGHWAY No.11 Rd., T. BANKLANG, A. MUEANG LAMPHUN, LAMPHUN, 51000 THAILAND.
FOR- AGBOGU HEALTHCARE PRODUCTS LIMITED; CITY PLAZA ONE, NO.6 ABAKILIKI STREET, AWKA, ANAMBRA STATE, NIGERIA.
51-1-20856-1-0003
BIM A
Dietary Supplement Product
60 Capsules แคปซูล | Net weight น้ำหนักสุทธิ 36 g. กรัม
Ingredients : ส่วนประกอบสำคัญ
One capsule (600 mg.) contains
ใน 1 แคปซูล (600 มก.) ประกอบด้วย
Black sesame extract สารสกัดจากงาดำ 200 มก. (33.33%)
Centella asiatica juice powder ผงน้ำใบบัวบก 104 มก. (17.34%)
Isolated soy protein โปรตีนสกัดจากถั่วเหลือง 100 มก. (16.67%)
Guava fruit juice powder ผงน้ำฝรั่ง 50 มก. (8.33%)
Mangosteen aril juice powder ผงน้ำเนื้อมังคุด 50 มก. (8.33%)
Capsule # 0 แคปซูล 96 มก. (16.00%)


DIRECTIONS : 2-3 capsules, 2-3 times a day, before meal or bedtime.
ขนาดรับประทาน : 2-3 แคปซูล วันละ 2-3 ครั้ง ก่อนอาหารหรือก่อนนอน
MANUFACTURED BY:
BANGKOK OFFICE:
ASIAN PHYTOCEUTICALS PUBLIC COMPANY LIMITED 89 AIA CAPITAL CENTER BUILDING 30TH FLOOR, RATCHADAPISEK Rd., DIN-DAENG, BANGKOK, 10400 THAILAND.
MANUFACTURING FACILITY:
NORTHERN REGION INDUSTRIAL ESTATE 84/3 MOO 4, HIGHWAY No.11 Rd., T. BANKLANG, A. MUEANG LAMPHUN, LAMPHUN, 51000 THAILAND.
FOR- AGBOGU HEALTHCARE PRODUCTS LIMITED; CITY PLAZA ONE, NO.6 ABAKILIKI STREET, AWKA, ANAMBRA STATE, NIGERIA.
51-1-20856-5-0047
BIM B
Dietary Supplement Product
60 Capsules แคปซูล Net Weight น้ำหนักสุทธิ 36 g. กรัม
Ingredients : ส่วนประกอบสำคัญ
One capsule (600 mg.) contains ใน 1 แคปซูล (600 มก.) ประกอบด้วย
ผงน้ำใบบัวบก 175 มก. (29.17%)
Centella asiatica juice powder
โปรตีนสกัดจากถั่วเหลือง 104 มก. (17.33%)
Isolated soy protein
ผงน้ำฝรั่ง 100 มก. (16.67%)
Guava fruit juice powder
สารสกัดจากงาดำ 75 มก. (12.5%)
Black sesame extract
ผงน้ำเนื้อมังคุด 50 มก. (8.33%)
Mangosteen aril juice powder
แคปซูล 96 มก. (16.00%)
Capsule # 0


DIRECTIONS : 3-4 capsules, 3 times a day, before meal or bedtime.
ขนาดรับประทาน : 3-4 แคปซูล วันละ 3 ครั้ง ก่อนอาหารหรือก่อนนอน
MANUFACTURED BY :
BANGKOK OFFICE:
ASIAN PHYTOCEUTICALS PUBLIC COMPANY LIMITED 89 AIA CAPITAL CENTER BUILDING 30TH FLOOR, RATCHADAPISEK Rd., DIN-DAENG, BANGKOK, 10400 THAILAND.
MANUFACTURING FACILITY:
NORTHERN REGION INDUSTRIAL ESTATE 84/3 MOO 4, HIGHWAY No.11 Rd., T. BANKLANG, A. MUEANG LAMPHUN, LAMPHUN, 51000 THAILAND.
FOR- AGBOGU HEALTHCARE PRODUCTS LIMITED; CITY PLAZA ONE, NO.6 ABAKILIKI STREET, AWKA, ANAMBRA STATE, NIGERIA.
51-1-20856-5-0001
BIM C
DIETARY SUPPLEMENT PRODUCT
Centella asiatica juice powder
Black sesame extract
Isolated soy protein
Guava fruit juice powder and
Mangosteen aril juice powder
60 Capsules Net weight 36 g. | 60 แคปซูล น้ำหนักสุทธิ 36 กรัม
Ingredients : ส่วนประกอบสำคัญ
One capsule (600 mg.) contains
ใน 1 แคปซูล (600 มก.) ประกอบด้วย
Centella asiatica juice powder ผงน้ำใบบัวบก 154 มก. (25.67 %)
Black sesame extract สารสกัดจากงาดำ 100 มก. (16.67%)
Isolated soy protein โปรตีนสกัดจากถั่วเหลือง 100 มก. (16.67%)
Guava fruit juice powder ผงน้ำฝรั่ง 100 มก. (16.67%)
Mangosteen aril juice powder ผงน้ำเนื้อมังคุด 50 มก. (8.32%)
Capsule # 0 แคปซูล 96 มก. (16.00%)


DIRECTIONS : 2 capsules, 2-3 times a day, before meal or bedtime.
ขนาดรับประทาน : 2 แคปซูล วันละ 2-3 ครั้ง ก่อนอาหารหรือก่อนนอน
MANUFACTURED BY :
BANGKOK OFFICE:
ASIAN PHYTOCEUTICALS PUBLIC COMPANY LIMITED 89 AIA CAPITAL CENTER BUILDING 30TH FLOOR, RATCHADAPISEK Rd., DIN-DAENG, BANGKOK, 10400 THAILAND.
MANUFACTURING FACILITY:
NORTHERN REGION INDUSTRIAL ESTATE 84/3 MOO 4, HIGHWAY No.11 Rd., T. BANKLANG, A. MUEANG LAMPHUN, LAMPHUN, 51000 THAILAND.
FOR- AGBOGU HEALTHCARE PRODUCTS LIMITED; CITY PLAZA ONE, NO.6 ABAKILIKI STREET, AWKA, ANAMBRA STATE, NIGERIA.
51-1-20856-1-0005
BIM D
(Black sesame extract, Isolated soy protein, Centella asiatica juice powder, Guava fruit juice powder and Mangosteen extract powder)
(Dietary Supplement Product)
60 Capsules Net weight 36.00 g. | 60 แคปซูล น้ำหนักสุทธิ 36.00 กรัม
Ingredients : ส่วนประกอบสำคัญ
One capsule (600 mg.) contains
ใน 1 แคปซูล (600 มก.) ประกอบด้วย
Black sesame extract สารสกัดจากงาดำ 250 มก. (41.67%)
Isolated soy protein โปรตีนสกัดจากถั่วเหลือง 104 มก. (17.34%)
Centella asiatica juice powder ผงน้ำใบบัวบก 50 มก. (8.33%)
Guava fruit juice powder ผงน้ำฝรั่ง 50 มก. (8.33%)
Mangosteen aril juice powder ผงน้ำเนื้อมังคุด 50 มก. (8.33%)
Capsule # 0 แคปซูล 96 มก. (16.00%)


DIRECTIONS : 3 capsules, 2-3 times a day, before meal or bedtime.
ขนาดรับประทาน : 3 แคปซูล วันละ 2-3 ครั้ง ก่อนอาหารหรือก่อนนอน
MANUFACTURED BY :
BANGKOK OFFICE:
ASIAN PHYTOCEUTICALS PUBLIC COMPANY LIMITED 89 AIA CAPITAL CENTER BUILDING 30TH FLOOR, RATCHADAPISEK Rd., DIN-DAENG, BANGKOK, 10400 THAILAND.
MANUFACTURING FACILITY:
NORTHERN REGION INDUSTRIAL ESTATE 84/3 MOO 4, HIGHWAY No.11 Rd., T. BANKLANG, A. MUEANG LAMPHUN, LAMPHUN, 51000 THAILAND.
FOR- AGBOGU HEALTHCARE PRODUCTS LIMITED; CITY PLAZA ONE, NO.6 ABAKILIKI STREET, AWKA, ANAMBRA STATE, NIGERIA.
51-1-20856-5-0045
BIM F
Dietary Supplement Product
60 Capsules แคปซูล Net weight น้ำหนักสุทธิ 36 g. กรัม
Ingredients : ส่วนประกอบสำคัญ
One capsule (600 mg.) contains
ใน 1 แคปซูล (600 มก.) ประกอบด้วย
Centella asiatica juice powder ผงน้ำใบบัวบก 175 มก. (29.17%)
Isolated soy protein โปรตีนสกัดจากถั่วเหลือง 104 มก. (17.33%)
Guava fruit juice powder ผงน้ำฝรั่ง 100 มก. (16.67%)
Black sesame extract สารสกัดจากงาดำ 75 มก. (12.50%)
Mangosteen aril juice powder ผงน้ำเนื้อมังคุด 50 มก. (8.33%)
Capsule # 0 แคปซูล 96 มก. (16.00%)


DIRECTIONS : 3 capsules, 3 times a day, before meal or bedtime.
ขนาดรับประทาน : 3 แคปซูล วันละ 3 ครั้ง ก่อนอาหารหรือก่อนนอน
MANUFACTURED BY :
BANGKOK OFFICE:
ASIAN PHYTOCEUTICALS PUBLIC COMPANY LIMITED 89 AIA CAPITAL CENTER BUILDING 30TH FLOOR, RATCHADAPISEK Rd., DIN-DAENG, BANGKOK, 10400 THAILAND.
MANUFACTURING FACILITY:
NORTHERN REGION INDUSTRIAL ESTATE 84/3 MOO 4, HIGHWAY No.11 Rd., T. BANKLANG, A. MUEANG LAMPHUN, LAMPHUN, 51000 THAILAND.
FOR- AGBOGU HEALTHCARE PRODUCTS LIMITED; CITY PLAZA ONE, NO.6 ABAKILIKI STREET, AWKA, ANAMBRA STATE, NIGERIA.
51-1-20856-5-0044
BIM H
Dietary Supplement Product
60 Capsules แคปซูล Net weight น้ำหนักสุทธิ 36 g. กรัม
Ingredients : ส่วนประกอบสำคัญ
One capsule (600 mg.) contains
ใน 1 แคปซูล (600 มก.) ประกอบด้วย
Centella asiatica juice powder ผงน้ำใบบัวบก 150 มก. (25.00%)
Guava fruit juice powder ผงน้ำฝรั่ง 100 มก. (16.67%)
Isolated soy protein โปรตีนสกัดจากถั่วเหลือง 100 มก. (16.67%)
Black sesame extract สารสกัดจากงาดำ 100 มก. (16.67%)
Mangosteen aril juice powder ผงน้ำเนื้อมังคุด 50 มก. (8.32%)
Capsule # 0 แคปซูล 100 มก. (16.67%)


DIRECTIONS : 3 capsules, 2 times a day, before meal or bedtime.
ขนาดรับประทาน : 3 แคปซูล วันละ 2 ครั้ง ก่อนอาหารหรือก่อนนอน
MANUFACTURED BY :
BANGKOK OFFICE:
ASIAN PHYTOCEUTICALS PUBLIC COMPANY LIMITED 89 AIA CAPITAL CENTER BUILDING 30TH FLOOR, RATCHADAPISEK Rd., DIN-DAENG, BANGKOK, 10400 THAILAND.
MANUFACTURING FACILITY:
NORTHERN REGION INDUSTRIAL ESTATE 84/3 MOO 4, HIGHWAY No.11 Rd., T. BANKLANG, A. MUEANG LAMPHUN, LAMPHUN, 51000 THAILAND.
FOR- AGBOGU HEALTHCARE PRODUCTS LIMITED; CITY PLAZA ONE, NO.6 ABAKILIKI STREET, AWKA, ANAMBRA STATE, NIGERIA.
51-1-20856-1-0019
BIM C
(Centella asiatica juice powder, Black sesame extract, Isolated soy protein, Guava fruit juice powder and Mangosteen aril juice powder)
(Dietary Supplement Product)
60 Capsules Net weight 36.00 g. | 60 แคปซูล น้ำหนักสุทธิ 36.00 กรัม
Ingredients : ส่วนประกอบสำคัญ
One capsule (600 mg.) contains
ใน 1 แคปซูล (600 มก.) ประกอบด้วย
Centella asiatica juice powder ผงน้ำใบบัวบก 150 มก. (25.00%)
Black sesame extract สารสกัดจากงาดำ 100 มก. (16.67%)
Isolated soy protein โปรตีนสกัดจากถั่วเหลือง 100 มก. (16.67%)
Guava fruit juice powder ผงน้ำฝรั่ง 100 มก. (16.67%)
Mangosteen aril juice powder ผงน้ำเนื้อมังคุด 50 มก. (8.32%)
Capsule # 0 แคปซูล 100 มก. (16.67%)


DIRECTIONS : 3 capsules a day, before meal or bedtime.
ขนาดรับประทาน : 3 แคปซูล ก่อนอาหาร หรือก่อนนอน
MANUFACTURED BY :
BANGKOK OFFICE:
ASIAN PHYTOCEUTICALS PUBLIC COMPANY LIMITED 89 AIA CAPITAL CENTER BUILDING 30TH FLOOR, RATCHADAPISEK Rd., DIN-DAENG, BANGKOK, 10400 THAILAND.
MANUFACTURING FACILITY:
NORTHERN REGION INDUSTRIAL ESTATE 84/3 MOO 4, HIGHWAY No.11 Rd., T. BANKLANG, A. MUEANG LAMPHUN, LAMPHUN, 51000 THAILAND.
FOR- AGBOGU HEALTHCARE PRODUCTS LIMITED; CITY PLAZA ONE, NO.6 ABAKILIKI STREET, AWKA, ANAMBRA STATE, NIGERIA.
51-1-20856-5-0042
CANCINO
DIETARY SUPPLEMENT PRODUCT
Net weight น้ำหนักสุทธิ 36 g. กรัม 60 Capsules แคปซูล
Ingredients : ส่วนประกอบสำคัญ
One capsule (600 mg.) contains
ใน 1 แคปซูล (600 มก.) ประกอบด้วย
Centella asiatica juice powder ผงน้ำใบบัวบก 154.0 มก. (25.67%)
Isolated soy protein โปรตีนสกัดจากถั่วเหลือง 100.0 มก. (16.67%)
Guava juice powder ผงน้ำฝรั่ง 100.0 มก. (16.67%)
Black sesame extract สารสกัดจากงาดำ 100.0 มก. (16.67%)
Mangosteen juice powder ผงน้ำมังคุด 50.0 มก. (8.32%)
Capsule # 0 แคปซูล 96 มก. (16.00%)


DIRECTIONS : 3-4 capsules, 3 times a day, before meal or bedtime.
ขนาดรับประทาน : 3-4 แคปซูล วันละ 3 ครั้ง ก่อนอาหารหรือก่อนนอน
MANUFACTURED BY :
BANGKOK OFFICE:
ASIAN PHYTOCEUTICALS PUBLIC COMPANY LIMITED 89 AIA CAPITAL CENTER BUILDING 30TH FLOOR, RATCHADAPISEK Rd., DIN-DAENG, BANGKOK, 10400 THAILAND.
MANUFACTURING FACILITY:
NORTHERN REGION INDUSTRIAL ESTATE 84/3 MOO 4, HIGHWAY No.11 Rd., T. BANKLANG, A. MUEANG LAMPHUN, LAMPHUN, 51000 THAILAND.
FOR- AGBOGU HEALTHCARE PRODUCTS LIMITED; CITY PLAZA ONE, NO.6 ABAKILIKI STREET, AWKA, ANAMBRA STATE, NIGERIA.
51-1-20856-5-0006
NOVIR
DIETARY SUPPLEMENT PRODUCT
60 Capsules แคปซูล | Net weight น้ำหนักสุทธิ 36 g. กรัม
Ingredients : ส่วนประกอบสำคัญ
One capsule (600 mg.) contains
ใน 1 แคปซูล (600 มก.) ประกอบด้วย
Centella asiatica juice powder ผงน้ำใบบัวบก 154 มก. (25.66%)
Isolated soy protein โปรตีนสกัดจากถั่วเหลือง 100 มก. (16.67%)
Guava fruit juice powder ผงน้ำฝรั่ง 100 มก. (16.67%)
Black sesame extract สารสกัดจากงาดำ 100 มก. (16.67%)
Mangosteen aril juice powder ผงน้ำเนื้อมังคุด 50 มก. (8.33%)
Capsule # 0 แคปซูล 96 มก. (16.00%)


DIRECTIONS : 2-3 capsules, 2 times a day, before meal or bedtime.
ขนาดรับประทาน : 2-3 แคปซูล วันละ 2 ครั้ง ก่อนอาหารหรือก่อนนอน
MANUFACTURED BY :
BANGKOK OFFICE:
ASIAN PHYTOCEUTICALS PUBLIC COMPANY LIMITED 89 AIA CAPITAL CENTER BUILDING 30TH FLOOR, RATCHADAPISEK Rd., DIN-DAENG, BANGKOK, 10400 THAILAND.
MANUFACTURING FACILITY:
NORTHERN REGION INDUSTRIAL ESTATE 84/3 MOO 4, HIGHWAY No.11 Rd., T. BANKLANG, A. MUEANG LAMPHUN, LAMPHUN, 51000 THAILAND.
FOR- AGBOGU HEALTHCARE PRODUCTS LIMITED; CITY PLAZA ONE, NO.6 ABAKILIKI STREET, AWKA, ANAMBRA STATE, NIGERIA.
51-1-20856-5-0021
Mylife 1CO
Dietary Supplement Product
60 Capsules แคปซูล | Net weight น้ำหนักสุทธิ 35.76 g. กรัม
Mylife1CO
Ingredients : ส่วนประกอบสำคัญ
One capsule (596 mg.) contains
ใน 1 แคปซูล (596 มก.) ประกอบด้วย
Guava fruit juice powder ผงน้ำฝรั่ง 100 มก. (16.78%)
Mangosteen aril juice powder ผงน้ำเนื้อมังคุด 100 มก. (16.78%)
Centella asiatica juice powder ผงน้ำใบบัวบก 100 มก. (16.78%)
Black sesame extract สารสกัดจากงาดำ 100 มก. (16.78%)
Isolated soy protein โปรตีนสกัดจากถั่วเหลือง 100 มก. (16.78%)
Capsule # 0 แคปซูล 96 มก. (16.10%)


DIRECTIONS : 2 capsules, 2-3 times a day, before meal or bedtime.
ขนาดรับประทาน : 2 แคปซูล วันละ 2-3 ครั้ง ก่อนอาหารหรือก่อนนอน
MANUFACTURED BY :
BANGKOK OFFICE:
ASIAN PHYTOCEUTICALS PUBLIC COMPANY LIMITED 89 AIA CAPITAL CENTER BUILDING 30TH FLOOR, RATCHADAPISEK Rd., DIN-DAENG, BANGKOK, 10400 THAILAND.
MANUFACTURING FACILITY:
NORTHERN REGION INDUSTRIAL ESTATE 84/3 MOO 4, HIGHWAY No.11 Rd., T. BANKLANG, A. MUEANG LAMPHUN, LAMPHUN, 51000 THAILAND.
FOR- AGBOGU HEALTHCARE PRODUCTS LIMITED; CITY PLAZA ONE, NO.6 ABAKILIKI STREET, AWKA, ANAMBRA STATE, NIGERIA.
51-1-20856-1-0018
Mylife
Dietary Supplement Product
(Centella asiatica juice powder, Black sesame extract, Isolated soy protein, Guava fruit juice powder and Mangosteen aril juice powder)
60 Capsules Net weight 36.00 g. | 60 แคปซูล น้ำหนักสุทธิ 36.00 กรัม
Ingredients : ส่วนประกอบสำคัญ
One capsule (600 mg.) contains
ใน 1 แคปซูล (600 มก.) ประกอบด้วย
Centella asiatica juice powder ผงน้ำใบบัวบก 150 มก. (25.00%)
Black sesame extract สารสกัดจากงาดำ 100 มก. (16.67%)
Isolated soy protein โปรตีนสกัดจากถั่วเหลือง 100 มก. (16.67%)
Guava fruit juice powder ผงน้ำฝรั่ง 100 มก. (16.67%)
Mangosteen aril juice powder ผงน้ำเนื้อมังคุด 50 มก. (8.32%)
Capsule # 0 แคปซูล 100 มก. (16.67%)


DIRECTIONS : 2-3 capsules, 2 times a day, before meal or bedtime.
ขนาดรับประทาน : 2-3 แคปซูล วันละ 2 ครั้ง ก่อนอาหารหรือก่อนนอน
MANUFACTURED BY :
BANGKOK OFFICE:
ASIAN PHYTOCEUTICALS PUBLIC COMPANY LIMITED 89 AIA CAPITAL CENTER BUILDING 30TH FLOOR, RATCHADAPISEK Rd., DIN-DAENG, BANGKOK, 10400 THAILAND.
MANUFACTURING FACILITY:
NORTHERN REGION INDUSTRIAL ESTATE 84/3 MOO 4, HIGHWAY No.11 Rd., T. BANKLANG, A. MUEANG LAMPHUN, LAMPHUN, 51000 THAILAND.
FOR- AGBOGU HEALTHCARE PRODUCTS LIMITED; CITY PLAZA ONE, NO.6 ABAKILIKI STREET, AWKA, ANAMBRA STATE, NIGERIA.
51-1-20856-5-0027
Mylife 1COA
Dietary Supplement Product
60 Capsules แคปซูล | Net weight น้ำหนักสุทธิ 35.76 g. กรัม
Ingredients : ส่วนประกอบสำคัญ
One capsule (596 mg.) contains
ใน 1 แคปซูล (596 มก.) ประกอบด้วย
Guava fruit juice powder ผงน้ำฝรั่ง 120 มก. (20.14%)
Mangosteen aril juice powder ผงน้ำเนื้อมังคุด 120 มก. (20.14%)
Centella asiatica juice powder ผงน้ำใบบัวบก 100 มก. (16.78%)
Black sesame extract สารสกัดจากงาดำ 80 มก. (13.42%)
Isolated soy protein โปรตีนสกัดจากถั่วเหลือง 80 มก. (13.42%)
Capsule # 0 แคปซูล 96 มก. (16.10%)

กลุ่มเป้าหมาย

คาดว่าในแอฟริกามีผู้ติดเชื้อ HIV/AIDS กว่า 25 ล้านคน และผู้ติดเชื้อไวรัสอื่นๆ ตลอดจนผู้ป่วยมะเร็งเป็นจำนวนมาก ความต้องการนวัตกรรมสุขภาพที่มีประสิทธิภาพ ปลอดภัย และเข้าถึงได้ จึงเป็นสิ่งจำเป็น

แอฟริกา ในหนึ่งปี

- ผู้ติดเชื้อ HIV ใหม่ 1.3 ล้าน
- ผู้ป่วยมะเร็งใหม่ 1.1 ล้าน
- รวมสองกลุ่ม 2.4 ล้าน

ไนจีเรีย ในหนึ่งปี

- ผู้ติดเชื้อ HIV ใหม่ 74,000 คน
- ผู้ป่วยมะเร็งใหม่ 128,000 คน
- รวมสองกลุ่ม 202,000 คน

แต่ละคน ใช้ เดือนละ 6 ขวด : 6 เดือน 36 ขวด

30,000 คน 6 เดือน ใช้ 1,080,000 ขวด

ประมาณการทุกผลิตภัณฑ์รวม
1,160,000 ขวด/ปี

สัญญา OEM และแต่งตั้งผู้แทนจำหน่าย

- เป็นผู้แทนจำหน่ายผู้เดียวในทวีปแอฟริกา แต่เพียงผู้เดียว 10 ปี
- ต้องมียอดจำหน่าย 1,160,000 ขวดต่อปี

การชำระค่าสินค้า

- 50% ก่อนวันส่งสินค้า 3 เดือน
- 50% ก่อนวันส่งมอบสินค้า

เริ่มเร็วที่สุด

เมื่อได้รับการอนุญาตจาก อย. ของไนจีเรีย หรือจากประเทศต่างๆ ในแอฟริกา